

We Claim:

1. ~~A combination comprising~~Use of an antibody specific for CD19 wherein said antibody comprises an HCDR1 region comprising sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising sequence MQHLEYPIT (SEQ ID NO: 6) ~~and venetoclax for use in~~ in the manufacture of a medicament for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia, wherein the antibody specific for CD19 is used in combination with venetoclax.
2. ~~— A combination~~ The use according to claim 1, wherein the antibody has ADCC activity.
3. ~~A combination~~ The use according to ~~claims~~ claim 1 or claim 2, wherein the antibody comprises a variable heavy chain comprising the sequence EVQLVESGGGLVKPGGSLKLSAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDAMYYCARGTYYYGTRVFDYW G QGTLTVSS (SEQ ID NO: 10) and a variable light chain ~~of comprising~~ the sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR MSNLNSGVPDRFSGSGSGTEFTLTISLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).
4. ~~— A combination~~ 4. The use according to any one of the preceding claims, wherein the antibody comprises a heavy chain constant domain comprising the sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE LLGGPDVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPMLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12).

5. ~~A combination~~The use according to any one of the preceding claims, wherein the antibody comprises a light chain constant domain comprising the sequence RTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (~~SEQ ID NO: 13~~)

6. ~~A combination~~RTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13).

6. The use according to any one of the preceding claims, wherein said antibody specific for CD19 and venetoclax are formulated in different pharmaceutical compositions.

7. The use according to any one of the preceding claims, wherein said antibody specific for CD19 and venetoclax are to be administered separately.

7. ~~A combination~~8. The use according to any one of the preceding claims, wherein:

(a) venetoclax is to be administered prior to administration of the antibody specific for CD19; or

8. ~~A combination~~(b) said antibody specific for CD19 is to be administered prior to venetoclax.

9. The use according to any one of ~~the preceding~~ claims 1 to 6, wherein said antibody specific for CD19 and venetoclax are to be administered simultaneously.

9. ~~A combination~~10. The use according to any one of the preceding claims, wherein said antibody specific for CD19 and venetoclax are to be administered at a time where both drugs are active in the patient at the same time.

~~10. — A combination 11. The use according to any one of the preceding claims for use₁ in the manufacture of a medicament for the~~ treatment of chronic lymphocytic leukemia.

~~11. — A combination 12. The use according to any one of the preceding claims for use₁ to 10, in the manufacture of a medicament for the~~ treatment of acute lymphoblastic leukemia.

~~12. — A combination 13. The use according to any one of the preceding claims for use₁ to 10, in the manufacture of a medicament for the~~ treatment of non-Hodgkin's lymphoma.

~~14. The use according to claim 13, wherein the non-Hodgkin's lymphoma is selected from the group consisting of~~ follicular lymphoma.

~~15. The use according to claim 13, wherein the non-Hodgkin's lymphoma is~~ small lymphocytic lymphoma.

~~16. The use according to claim 13, wherein the non-Hodgkin's lymphoma is~~ mucosa-associated lymphoid tissue, lymphoma.

~~17. The use according to claim 13, wherein the non-Hodgkin's lymphoma is~~ marginal zone, lymphoma.

~~18. The use according to claim 13, wherein the non-Hodgkin's lymphoma is~~ diffuse large B cell, lymphoma.

~~19. The use according to claim 13, wherein the non-Hodgkin's lymphoma is~~ Burkitt's, and lymphoma.

~~20. The use according to claim 13, wherein the non-Hodgkin's lymphoma is~~ mantle cell lymphoma.